Submit Your Feeds

Business News • PR NewsWire • New Analyses of Denosumab Pivotal Phase 3 Trials Reinforce Potential Advantages Over Standard of Care

New Analyses of Denosumab Pivotal Phase 3 Trials Reinforce Potential Advantages Over Standard of Care
New Analyses of Denosumab Pivotal Phase 3 Trials Reinforce Potential Advantages Over Standard of Care

THOUSAND OAKS, Calif., June 5 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced positive results from several new analyses of two Phase 3 trials studying denosumab compared with Zometa® (zoledronic acid), the current standard of care, for the treatment of bone metastases in patient

View More : http://www.prnewswire.com/news-releases/new-analyses-of-denosumab-pivotal-phase-3-trials-reinforce-potential-advantages-...
Releted News by prnewswire
Adding Novartis Drug Zometa® to Chemotherapy Significantly Improved Overall Survival in Study of Newly Diagnosed Multiple Myeloma Patients
New Analyses of Denosumab Pivotal Phase 3 Trials Reinforce Potential Advantages Over Standard of Care
Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting
Parents Magazine's Free Baby Photo Contest Ends June 19
ENERGY GLOBE World Award Goes to India
Home Sitemap Contact Us
© businessNewsNewsNews.com